滚动资讯
Endpoints NewsLack of specifics on obesity pill sales hover over Lilly’s first quarterEndpoints NewsThe R&D 15: How pharma's top companies spent, won and lost on drug researchEndpoints NewsNovartis unveils North Carolina factory as final new build in $23B US expansionFierceBiotechGSK对Alector的7亿美元押注失败，阿尔茨海默症药物二期试验未达标FierceBiotechAvalyn携3亿美元超额募集赴纳斯达克IPO，推进改良型呼吸药物研发FierceBiotech阿斯利康以2500万美元从Pinetree获得临床前EGFR降解剂Novo Nordisk诺和诺德的GLP-1药物优势在礼来临床试验胜利后是否正在减弱？Siemens Healthineers西门子医疗：诊断业务以60亿欧元退出，股价触底后即将进行分拆BioPharma DiveAvalyn 寻求更好的肺部药物，在IPO中融资3亿美元Sinopharm Chemical Reagent Co., Ltd.中国稳定剂价格 - 市场洞察 - IndexBoxeLifeThe FAM53C/DYRK1A axis regulates the G1/S transition of the cell cycleInsilico Medicine英科智能获得Rentosertib吸入溶液IND批准，推进特发性肺纤维化靶向治疗 - BioPharma APAC
WuXi AppTec 2025年12月4日

After dodging Biosecure threat, WuXi AppTec faces new security scrutiny from Pentagon: Bloomberg - Fierce Pharma

After dodging Biosecure threat, WuXi AppTec faces new security scrutiny from Pentagon: Bloomberg - Fierce Pharma

原文
暂时没有全文，请查看原始来源。